Comprehensive Evaluation of Tirbanibulin for Treating Actinic Keratosis: A European Multi-Criteria Decision Analysis Study
By
Carola Berking
Rafael Botella
Andrea Carugno
Giovanna Gambarelli
Josep Malvehy
Elvira Moscarella
Arianna Petracca
Gregorio Romero
Julio Sosa
Eggert Stockfleth
Jose Luis Trillo
March 12, 2026
Clinical Scorecard: Comprehensive Evaluation of Tirbanibulin for Treating Actinic Keratosis: A European Multi-Criteria Decision Analysis Study
At a Glance
Category Detail
Condition Actinic Keratosis (AK) Key Mechanisms Tirbanibulin acts as an antiproliferative agent by inhibiting microtubule polymerization and disrupting Src kinase signaling. Target Population Adults with non-hyperkeratotic, non-hypertrophic AK on the face or scalp. Care Setting Outpatient dermatology clinics.
Key Highlights
Tirbanibulin scored 0.622 on a -1 to +1 scale, indicating positive reception. Safety and tolerability were prioritized by stakeholders over efficacy differences. Tirbanibulin is approved by EMA and FDA for treating AK in specified areas. Recurrence of AK lesions is common, with up to 75% requiring retreatment within a year. Multi-criteria decision analysis (MCDA) integrates diverse stakeholder perspectives. Guideline-Based Recommendations
Diagnosis
Clinically evident lesions should be treated with lesion-directed therapies. Field-directed therapies are recommended for multiple or subclinical lesions. Management
Topical agents are the gold standard for field-directed therapy. Monitoring & Follow-up
Monitor for recurrence and progression to cutaneous squamous cell carcinoma. Risks
Cumulative 10-year risk of cSCC increases with multiple lesions. Patient & Prescribing Data
Adults with non-hyperkeratotic, non-hypertrophic AK lesions.
Tirbanibulin is a 5-day topical therapy targeting precancerous keratinocytes.
Clinical Best Practices
Incorporate patient preferences in treatment decisions. Utilize MCDA for a comprehensive evaluation of treatment options. References
